[[{“value”:”
Unlike GLP-1 agonist drugs marketed for weight loss, new Amylyx Pharmaceuticals drug avexitide blocks its target receptor. Amylyx plans to advance this GLP-1 antagonist into Phase 3 testing for post-bariatric hypoglycemia, a rare condition in which blood sugar levels drop precipitously.
The post Amylyx Aims to Help Patients With a Novel GLP-1 Drug, But Not the Way You Think appeared first on MedCity News.
“}]]
